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INTRODUCTION 
Oral delivery of drugs is by far the most 
preferable route of drug delivery due to the ease of 
administration, patient compliance and flexibility in 
formulation. From immediate release to site specific 
delivery, oral dosage forms have greatly progressed. It is 
evident from the recent scientific and patent literature that 
an increased interest in novel dosage forms that are 
retained in the stomach for a prolonged and predictable 
period of time exists today in academic and industrial 
research groups. One of the most feasible approaches for 
achieving a prolonged and predictable drug delivery 
profile in the GI tract is to control the gastric residence 
time. Dosage forms with a prolonged GRT, i.e. gastro 
retentive dosage forms (GRDFs) will provide us with new 
and important therapeutic options1. 
 Gastric retention will provide advantages such as 
the delivery of drugs with narrow absorption windows in 
the small intestinal region. Also, longer residence time in 
the stomach could be advantageous for local action in the 
upper part of the small intestine, e.g., treatment of peptic 
ulcer disease. Furthermore, improved bioavailability is 
expected for drugs that are absorbed readily in the GI tract 
upon release such drugs can be delivered ideally by slow 
release from the stomach for sustained action 2. 
Microballons are gastro-retentive drug delivery 
systems based on non-effervescent approach. Microballons 
are in strict sense, spherical empty particles without core. 
They are characteristically free flowing powders consisting 
of proteins or synthetic polymers, ideally having a size less 
than 200 micrometer. Solid biodegradable microballons 
incorporating a drug dispersed or dissolved throughout 
particle matrix have the potential for controlled release of 
drugs 3. Gastro-retentive floating microballons are low-
density systems that have sufficient buoyancy to float over 
gastric contents and remain in stomach for prolonged 
period. As the system floats over gastric contents, the drug 
is released slowly at desired rate resulting in increased 
gastric retention with reduced fluctuations in plasma drug 
concentration. When microballons come in contact with 
gastric fluid the gel formers, polysaccharides, and 
polymers hydrate to form a colloidal gel barrier that 
controls the rate of fluid penetration into the device and 
consequent drug release. As the exterior surface of the 
dosage form dissolves, the gel layer is maintained by the 
hydration of the adjacent hydrocolloid layer. The air 
trapped by the swollen polymer lowers the density and 
confers buoyancy to the microballons. However a minimal 
gastric content needed to allow proper achievement of 
buoyancy.  
The mesalamine hydrochloride requires frequent 
dosing due to short biological half-life (5hr) and absorbed 
20-30% orally. The traditional oral sustained release 
formulations release mesalamine hydrochloride but 
erratically absorbed through the intestine and mucosal wall 
of large intestine were the narrow absorption window exist 
is also responsible for colonic metabolism and poor 
bioavailability of drug (10-35%).Therefore sustained 
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release dosage form of mesalamine hydrochloride prepared 
by the conventional technology may not be very successful 
and clinically acceptable sothat controlled release 
intragestric floating microballons formulation of 
mesalamine hydrochloride eliminates the problems 
associated with conventional dosage forms 4 . 
MATERIAL 
Eudragit S-100 and Eudragit RS-100 was generously 
supplied as a gift samples by Rohm GmBH, Germany. 
Mesalamine Hydrochloride generously supplied as a gift 
sample from Sun Pharma Vadodara, Polyvinyl alcohol, 
Dichloromethane and ethanol were purchased from CDH 
India. All other chemicals and reagents were used of 
analytical grade. 
METHOD AND PREPARATION OF 
MICROBALLONS FORMULATION 
Microballons with an internal hollow structure were 
prepared by solvent diffusion evaporation method 
described by Kawashima et al., (2001)5 with little 
modification. For this 500 mg of eudragit S-100 and 500 
mg of eudragit RS-100 was dissolved in 1:1 (ethanol: 
dichloromethane) then 100 mg of mesalamine was 
homogeneously dispersed in it. This solution was slowly 
introduced into 200 ml of 0.75% w/v PVA solution with 
constant stirring at 400 rpm using a mechanical stirrer 
equipped with a blade propeller (Remi, India) for 3-4 hr. 
The microballons were formed, collected by filtration, 
washed three times with distilled water and dried at room 
temperature. 
Optimization of Formulation and Process Variables 
Various formulation and process variables i.e. polymer and 
drug concentration, phase volume ratio, surfactant 
concentration, stirring time and stirring speed which could 
affect the preparation and properties of microspheres were 
identified and studied. The optimization was done on the 
basis of particle size and drug entrapment efficiency.
 
Table 1: The various formulation and process variables for preparation of microballons 
S.No. Formulation code (S) Formulation / Process      variables Particle size (µm) Particle Shape 
 
1. 
 
MC1 
Eudragit S-100 and Eudragit RS-100 (%w/w)  
65.71.4 
Hollow 
Ellipsoidal 1:1 
2. MC2 1:2 78.22.5 Hollow Circular 
3. MC3 1:3 91.41.92 Circular  
4. MC4 1:4 128.33.3 Irregular 
  Mesalamine Hydrochloride Conc. (% w/w)  % EE 
1. MC2D1  40:100 71.43.1 82.81.5 
2. MC2D2  60:100 79.42.1 87.51.4 
3. MC2D3  80:100 83.32.6 91.21.8 
4. MC2D4  100:100 85.42.1 75.22.2 
  Surfactant PVA conc. (% w/v)   
1. MC2D3E1 0.5 89.43.4 82.53.2 
2. MC2D3E2 0.75 81.22.9 90.23.4 
3. MC2D3E3 1.0 78.62.4 73.81.6 
4. MC2D3E4 1.25 66.81.9 67.71.9 
  Stirring Speed (rpm)   
1. MC2D3E2R1 300 88.43.9 82.83.9 
2. MC2D3E2R2 400 74.23.5 91.13.2 
3. MC2D3E2R3 500 68.22.7 74.32.5 
  Temperature ( °C)   
1. MD4C5E2R2T1 25 °C 81.43.1 82.81.5 
2. MD4C5E2R2T2 37 
°
C 74.42.1 87.51.4 
3. MD4C5E2R2T3 45 °C 87.32.6 77.21.8 
 
Optimization of polymer (Eudragit S-100 and Eudragit 
RS-100) concentration 
For optimization of polymer concentration, the 
microballons formulations were prepared with varying 
concentration of Eudragit S-100 and Eudragit RS-100 i.e. 
1:1 to 1:4 % w/w) while keeping other parameters 
constant. Optimization was done on the basis of average 
particle size and shape. The observations are recorded in 
Table 1. 
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Optimization of Mesalamine Hydrochloride 
concentration 
For optimization of drug concentration, the microballons 
formulations (MC2) were prepared with varying 
percentage of mesalamine viz. 40:100, 60:100, 80:100 % 
w/w of drug while keeping other parameters constant. 
Optimization was done on the basis of drug loading and 
particle size. The observations are recorded in Table 1. 
Optimization of surfactant (PVA) concentration  
For optimization of surfactant (PVA) concentrations, the 
microballons formulation (MC2D3) was prepared with 
varying concentrations of surfactant viz 0.5 to 1.25 % w/v 
in external phase while keeping the other variables 
constant. Furthermore optimization was done on the basis 
of drug loading and particle size. The observations are 
recorded in Table 1. 
Optimization of stirring speed 
For the optimization of stirring speed, formulation 
(MC2D3E2) was selected and microballons were prepared 
by taking varying stirring speed i.e. 300, 400 and 500 
rpm by mechanical strring (Remi, India) while keeping the 
other variables constant. The optimization was done on the 
basis of average particle size and maximum % drug 
loading. The observations are recorded in Table 1.       
Optimization of temperature  
For the optimization of temperature formulation 
(MC2D3E2R2) was selected and microballons formulation 
were prepared by taking varying stirring time i.e. 250C, 
370C and 450C while keeping the other variables constant. 
The optimization was done on the basis of average particle 
size and maximum % drug loading efficiency. The 
observations are recorded in Table 1. 
On the basis of formulation and process variable studies 
the optimized microballons were prepared by the following 
formula:
 
Table 2: The optimized variables for the preparation of microballons were selected as follows 
S. No. Variables Optimized value Final code for optimized 
preparation 
1. Eudragit S-100: Eudragit RS-100 Conc. (% w/w).  1:2  
 
MD4C5E2R2T2 
2. Mesalamine Conc. (%w/w) 80 :100 
3. PVA  Conc. 1.5 (% w/v) 
5. Stirring speed 500 rpm 
6. Temperature ( °C) 37 °C 
 
CHARACTERIZATION OF OPTIMIZED 
MICROBALLONS FORMULATION 
Scanning electron microscope (SEM) for surface 
morphology study       
SEM was used as a visualizing aid for surface 
morphology. The samples for SEM were prepared by 
lightly sprinkling the microspheres powder on a double 
adhesive tape, which was stuck on an aluminium stub. The 
stubs were then coated with gold to a thickness of about 
300 Å using a sputter coater. All samples were 
examined under a  scann ing  electron  m i cr oscope  
(LEO 435 VP, E indh oven  Neth er lands ) a t  an  
acceleration voltage of 25 kV and photomicrographs were 
taken at suitable magnification.  
 
 
                   
          Figure 1: (A) Phase contrast photograph (100X)        (B) SEM Photomicrograph of microballons at (650X) 
Average particle size, surface charge and polydispersity 
index  
The average particle size was determined by optical 
microscopy method using calibrated stage and ocular 
micrometer (Erma, Japan). The particle size distributions 
are represented by the average size. The polydispersity 
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index is a dimensionless measure for the broadness of a 
particle size distribution and can be used for the evaluation 
of microspheres formulation. The polydispersity index 
(PDI) is a dimensionless measure for the broadness of a 
particle size distribution and was calculated using the 
following formula: 
PDI = 
size particle Average
deviation  Standard
-----------------------(1) 
Theoretically polydispersity index is zero for a 
monodisperse colloidal suspension. However the standard 
dispersion of particles with a PDI of about 0.05 is 
considered as monodispersed and with PDI greater than 
0.5 is assumed to have a broad size distribution  6. The zeta 
potential of a particle is the overall charge that the particle 
acquires in a particular medium and measured by a 
Zetasizer (Malvern Instruments, UK). The magnitude of 
the measured zeta potential is an indication of the repulsive 
force that is present and can be used to predict the long 
term stability of the product. 
 
Table 3: Characterization of optimized microballons formulation 
S. No. Formulation 
Code  
Particle size         
(µm) 
Zeta Potential 
(mV) 
 PDI % EE 
1. MD4C5E2R2T2 78.2 ±3.4 -5.4                          0.37 91. 3 ± 1.2% 
*  Eudragit S-100: Eudragit RS-100 Conc..: 1:2  (% w/w),   drug conc. :  (80 % w/w),  pva conc. : (0.75 % w/v),  stirring speed: 500  rpm  and temperature 37 °C. Values are expressed as 
mean ±SD, n=3. 
In vitro buoyancy test  
The floating test of optimized mesalamine hydrochloride 
microballons formulation (MD4C5E2R2T2) was carried 
out using dissolution test apparatus USP XXII method II. 
500 mg of microballons were immersed in 900 ml 
simulated gastric fluid SGF (pH 1.2) maintained at 37 ± 
2°C, which was agitated by a paddle rotated at 100 rpm. 
The paddle blades were positioned at the surface of 
dissolution medium. The microballons floating on the 
surface of SGF (pH 1.2) were recovered with a sieve No 
120 (34µm) at every 1 hr time interval for 8 hours. The 
microballons so collected were dried and weighed. The 
floating percentage of the microballons was defined as the 
weight ratio of the floating microballons against the total 
weight of microballons in the floating test. The buoyancy 
of the microballons was calculated by the following 
equation: 
100
sQ  fQ
fQ  (%)Bouyancy 

 -------------------- (2) 
where Qf  and Qs are the weights of the floating and settled 
microballons respectively. The buoyancy (%) of optimized 
mesalamine hydrochloride microballons formulation in 
SGF (pH 1.2) is shown in Figure 2 and 3.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Photographs of in vitro buoyancy of optimized microballons in SGF   (PH 1.2) 
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Figure 3: % Buoyancy of optimized microballons formulations in SGF (pH 1.2) 
Entrapment efficiency and in vitro drug release 
100 mg of microballons were taken, crushed by trituration 
and suspended in a 10 ml of dichloromethane for 
digestion of the microballons. The digested homogenate 
was centrifuged at 3000 rpm for 5 min filter through of 
0.2 μm (Millipore, USA). After appropriate dilution with 
0.1N HCl mesalamine concentration was assayed 
spectrophotometrically (Shimadzu 1800, Japan) at 300 
nm. The encapsulation e f f i c i en c y (EE) and the loading 
ca pa ci t y (LC) o f  t h e  microballons for mesalamine 
were calculated by the following equations: 
% EE = (X-Y)/X × 100% ---------------------------- (3) 
% LC = (X-Y)/Z × 100% -----------------------------(4) 
Where X is the total amount of the d r u g  added, Y was 
the free amount of the d r u g  in the supernatant, and Z is 
the weight of microballons. 
The in vitro mesalamine release study from 
microspheres was carried out by the paddle type-II 
dissolution apparatus specified in USP XXIII. For this 500 
mg of microspheres was spread over the surface of 900 ml 
of dissolution medium. The content was rotated at 100 rpm 
by placing the paddle on surface but dipped medium and 
thermostatically controlled at 372°C. Perfect sink 
condition was prevailed during the drug dissolution. The 
release was tested in dissolution medium of SGF (pH 1.2) 
and PBS (pH 7.4). An aliquot of the release medium was 
withdrawn at predetermined time intervals and an 
equivalent amount of fresh medium was added to the 
release medium. The collected samples were filtered 
through 0.45µm-syringe filter (Millipore, India) and 
analyzed spectrophotometricaly. The observations are 
graphically shown in Figure 5. 
 
 
Figure 4: % cumulative mesalamine released from optimized microballons formulation in (A) SGF (pH 1.2) and (B) PBS 
(pH 7.4). 
STABILITY STUDIES: 
Effect of storage temperature on structural integrity and 
particles size  
The change in structural integrity and particles size of the 
optimized microballons formulation when stored in amber 
colored glass bottles at 41°C, 251°C and 401°C 
temperatures was determined using optical microscopy 
method (Erma, Japan) after a definite period of time of  i.e. 
15, 30 and 45 days.  
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Figure 5: Effect of storage temperature on particle size of microballons formulation. 
 
Effect of storage on % residual drug content 
The % residual drug content of stored optimized 
microballons formulation after storage for a specified 
period of time i.e. 15, 30 and 45 days was determined by 
digesting the microballons  with 5 ml of dichloromethane 
then the digested homogenate was centrifuged at 3000 
rpm for 5 min filter through of 0.2 μm (Millipore, USA). 
After appropriate dilution with PBS (PH-7.4) mesalamine 
was assayed spectrophotometrically at 300 nm. The % 
residual drug content of each sample was determined in 
triplicate and values are shown in Figure 7.
 
 
Figure 6: Effect of storage temperature on % residual drug content in microballons formulation. 
 
IN VIVO RADIOGRAPHICAL STUDY 
In order to assess the gastro-retentive efficacy and 
buoyancy microballons formulation, the % buoyancy was 
determined by using barium sulphate X-ray contrast 
medium containing 15% barium sulphate. The study was 
carried out with three healthy male rabbits free of 
detectable gastrointestinal diseases or disorders. The study 
was carried out under the guidelines compiled by CPCSEA 
(Committee for the purpose of control) Supervision of 
Experiments on Animal, Ministry of Culture, Government 
of India and the local institutional Animal Ethics 
Committee of Adina institute of pharmaceutical sciences 
approved the study protocol. The rabbits were fasted 
overnight. The rabbits were administered optimized 
microballons formulation (MD4C5E2R2T2) with 25 ml of 
water and intragastric behaviour of the microballons was 
observed by taking a series of X- ray photographs at 
different time intervals as shown in Figure 8 (a, b, c, d).
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Figure 7: X- ray photographs of rabbit stomach  after administration of optimized microballons  formulation after different 
time intervals. 
IN VIVO ANTI-INFLAMMATORY ACTIVITY  
The albino rats (150-200) gm of either sex were randomly 
distributed into four groups containing 6 rats in each group 
and they kept under standard laboratory housing 
conditions. The animal weight range. They were fasted for 
24 hr before drug treatment. The animals were deprived of 
food and water during the experiment. The initial paw 
volume of right and left paw of each group of rats were 
determined by mercury displacement method 7. Right paw 
of each groups of animal and kept as control. 
Rats of group I were administered 0.1 ml of (1% 
w/v) carrageenan in the plantar region of the left paw and 
kept as a negative control group. The groups II were 
administered 10 ml solution of plain drug (equivalent to 50 
mg/kg of mesalamine hydrochloride p.o) 30 min prior 
administration 0.1 ml of (1% w/v) carrageenan in the 
plantar region of the left paw. The groups III were 
administered 10 ml optimized microballons 
(MD4C5E2R2T2) suspension (equivalent to 50 mg/kg of 
mesalamine hydrochloride p.o) 30 min prior administration 
0.1 ml of (1% w/v) carrageenan in the plantar region of the 
left paw. 
 
Table 4: Data for anti inflammatory activities of optimized microballons (MD4C5E2R2T2) formulation 
S. 
No. 
Formulation code Dose 
Paw volume measured by mercury displacement (mL) 
Time( min) 
0 15 30 60 120 
R L R L R L R L R L 
1 
Control  (0.1 ml of 1% 
w/v carrageenan) 
50 mg/kg 0.3 0.3 0.3 0.9 0.3 1.3 0.3 1.6 0.3 1.7 
2 Plain drug solution 
Equivalent to (50 
mg/kg of mesalamine 
hydrochloride) 
0.3 0.3 0.3 0.6 0.3 0.9 0.3 0.9 0.3 0.8 
3 MD4C5E2R2T2 
Equivalent to (50 
mg/kg of mesalamine 
hydrochloride) 
0.3 0.3 0.3 0.4 0.3 0.5 0.3 0.5 0.3 0.4 
 
RESULT AND DISCUSSION 
Eudragit S-100 and Eudragit RS-100 microballons were 
prepared by solvent diffusion method as reported by 
Kawashima et al., (2001). 1:2 Eudragit S-100 and Eudragit 
RS-100 matrix solution was sequentially dispersed in 
0.75% w/v PVA solution. PVA solution was chosen as the 
external phase because ethanol/ dichloromethane mixture 
Ashish et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(3), 7-15   14 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 
as an internal phase is not miscible with PVA solution and 
the Eudragit S-100 and Eudragit RS-100 is not soluble in 
it. As the dispersed droplets of Eudragit S-100 and 
Eudragit RS-100 solution collided in PVA solution, they 
formed an inter polymer complex. The droplets of polymer 
gradually solidified and forming a hollow cavity by 
ethanol and DCM diffusion from the internal phase. The 
effect of formulation variables e.g. polymer ratio, drug 
concentration, surfactant concentration and process 
variables e.g. stirring speed and temperature were studied 
in order to optimized the formulation.  These variables 
influence the shape, size and total drug loading efficiency 
and in vitro drug release hence these parameters were 
optimized to prepare microballons of small size, good drug 
loading efficiency and good drug release at the 
gastrointestinal pH. 
 Eudragit S-100 and Eudragit RS-100 employed 
in the preparation of microballons formulation was 
optimization by varying ratio of concentration viz. 1:1, 1:2, 
1:3 and 1:4 % w/w etc. The formulation was optimized on 
the basis of average particle size and shape. Increasing the 
concentration of Eudragit RS-100, particle size increased 
but above 1:2 polymer ratio the shape was drastically 
changed to ellipsoidal and deformed integrity. So that 
formulation MC2 showed size of 78.22.5 µm with hollow 
in nature and circular in shape (Table 1) were selected as 
optimum for study. 
 The loading of drug was also optimized on the 
basis of average particle size and maximum drug 
entrapment efficiency. For this microballons formulation 
were prepared with varying concentration mesalamine 
hydrochloride viz. 40, 60, 80 and 100 mg /100 mg of 
polymer. It was observed that on increasing the 
concentration of drug, the entrapment efficiency increased 
upto 80 mg. while on further increasing drug concentration 
the entrapment efficiency gradually decreased. This could 
be due to the saturation of polymer with the drug and 
particle size does not significantly change was observed 
(Table 1) sothat formulation MC2D3 was selected for 
further optimization process. 
The particle size found to be decreased upon 
increasing the concentration of PVA upto 0.75% w/v. This 
might be due to the decrease the surface tension between 
organic phase and aqueous phase which ultimately seem to 
allow formulation of micro size range particles. Optimum 
size of particles 81.22.9 µm with 90.23.4% drug 
entrapment were obtained at surfactant concentration 0.75 
%w/v (Table 1). However on further increasing surfactant 
concentration although the particle size decrease because 
of the formation of micelles but entrapment efficiency also 
decrease because of the leaching out of the drug sothat 
formulation MC2D3E2 was selected for further 
optimization process. 
 The process variable, stirring speed was 
optimized in terms of average particle size and maximum 
drug entrapment efficiency. Increase in stirring speed 
decrease an average particle size of microballons was 
observed. At 400 rpm formulation MC2D3E2R2 produced 
size distribution 74.23.5 µm with hollow and spherical 
shape with 91.13.2% drug entrapment efficiency (Table 
1).  
 Average particle size of microballons reduces 
with increased in temperature. Narrow size distribution 
74.42.1 µm with hollow shape and 87.51.4% 
entrapment efficiency was found to formulation 
MD4C5E2R2T2 at 37
°C temperature. Temperature for 
more than 37°C causes the external phase to separate due 
to agglomeration of the polymer (Table 1). 
The scanning electron microscopic 
photomicrograph of the optimized microballons 
formulations (MD4C5E2R2T2) showed spherical in shape 
having hollow cavity. This could be due to the evaporation 
of solvent during the preparation of microballons (Figure 
1). 
 In vitro buoyancy test of optimized microballons 
formulation was studied in SGF (pH 1.2) showed that the 
percentage buoyancy of microballons formulation was 
significantly decreased after 5 hr (Figure 3) suggesting that 
the density of microballons increased because water 
permeated into the hollow cavity of polymer which may be 
erode and swollen of the polymer matrix. 
  In vitro mesalamine hydrochloride releases from 
optimized microballons (MD4C5E2R2T2) were carried 
out in SGF (pH 1.2) and PBS (pH 7.4).  No initial burst 
release was observed in any medium suggested that the 
mesalamine hydrochloride molecules are entrapped over 
the hollow cavity of the microballons. Nearly linear 
relationship between the % cumulative release of 
mesalamine hydrochloride and the square root of time was 
obtained for the first 10 hr suggested that the microballons 
formulation follows a diffusion controlled drug release 
mechanism (Lee, 1985) 8. The % Cumulative amount of 
drug release was found 91.23.5% in SGF (pH 1.2), 
89.23.5% in PBS (pH 7.4) upto 24 hrs. The results clearly 
suggested that microballons formulation could be used for 
sustained drug delivery purpose. 
 Stability studies were carried out with optimized 
formulation MD4C5E2R2T2 which was stored for a period 
of 45 days at 4±1°C, 25±1°C and 40±1°C. The particle 
size of formulation was determined by optical microscopy 
using a calibrated ocular micrometer. The particle size of 
the microballons was found to increase at 25±1°C may be 
attributed to the aggregation of microballons at higher 
temperature. At 401°C the microballons aggregated and a 
change in spherical shape to ellipsoidal shape with 
irregular hollow cavity of microballons was observed i.e. 
these microballons were unstable at higher temperature 
like 401°C (Figure 5). The percent residual drug content 
of the optimized formulation are shown in (Figure 6). It 
was observed that the formulation stored at 4±1°C and 
25±1°C was quite stable as fewer drugs was degraded on 
storage for 45 days while it was quite unstable at 40±1°C 
for 45 days. 
X-ray contrast medium containing microballons was 
conducted to determine the in vivo floating performance and 
assessment of gastroretentive of the formulation. X-ray 
photograph taken after each 1hr interval shows intragastric 
behavior of the microballons.  It is clear from the X- ray 
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photographs that microballons remained buoyant even after 4 
hrs (Figure 7) which indicated that gastroretentive property 
obtained by microballons formulation. 
 Anti inflammatory activity of optimized 
microballons formulation in carrageenan induced rats 
showed when animals of group I acute inflammation were 
produced by injecting 0.1 ml of (1% w/v) carrageenan in 
the plantar region of the left paw. The paw volume 
measured by mercury displacement was found to be 1.7 ml 
after 2 hr. In case of animals of group II, which were 
administered 10 ml plain drug solution (equivalent to 
50mg/kg of mesalamine hydrochloride) 30 min prior to 
administration of 0.1 ml of (1% w/v) carrageenan in the 
plantar region of the left paw. The paw volume was 
recorded 0.8 ml after 2 hr. The group III of animal were 
administered 10 ml suspension of optimized microballons 
formulation MD4C5E2R2T2 (equivalent to 50mg/kg of 
mesalamine hydrochloride) 30 min prior to administration 
of 0.1 ml of (1% w/v) carrageenan in the plantar region of 
the left paw. The paw volume was registered 0.4 ml after 2 
hr (Table 4). The results showed that the microballons 
formulation released mesalamine hydrochloride released 
slowly which is desirable for the absorption of drug 
through upper part of the gastrointestinal tract where the 
absorption window exists and will maintain the peak 
serum level for a long time. Therefore it is clear from this 
study that the microballons formulations protect paw 
odeama/ inflammation completely.  
CONCLUSION 
The result obtained from all the experiments suggested that 
it is possible to prepare an intragastric floating and 
sustained release hollow microballons preparation using 
combination of Eudragit S-100 and Eudragit RS-100 by  
solvent evaporation method. Hollow microballons drug 
delivery system provides the possibility of enhancing the 
bioavailability and control the release of mesalamine 
hydrochloride exhibiting absorption window by prolonging 
the gastric emptying time ensuring availability of drug at 
the absorption site for the desired period of time. The 
hollow microballons showed a good buoyancy and drug 
release properties sothat it has a great potential for its use 
both in powder form for dry suspension and granular form 
for tableting.  
ACKNOWLEDGEMENT  
The authors thank to AIIMS, New Delhi for providing me 
the facilities of SEM study of my developed formulation. 
NIPER Chandigarh for particle size and zeta potential 
study. Sun Pharma Vadodara, India for supplying 
mesalamine hydrochloride drug as a gift sample. Adina 
Institute of Pharmaceutical Sciences, Sagar (M.P), India 
for permission of in vivo studies. 
DECLARATION OF INTEREST 
The authors report no conflicts of interest. The authors 
alone are responsible for the content and writing of this 
article.
 
REFERENCES  
1. Garg S, Sharma S, Gastroretentive drug delivery systems, Pharma 
Tech, 2003, 160-166. 
2. Gutierrez RJ, Omidian H, Shah K, Progress in gastroretentive drug 
delivery system, Business Briefing, PharmaTech, 2003, 6,152-161. 
3. Shivkr HG, Vishakanta GD, Pramod Kr TM, IJPER, 2004, 38, 62-
73. 
4. Bary  El, Ahmed Abd, Aboelwafa AA, Sharabi A, Ibrahim M, 
In fluen ce of some formu lat ion var iables on the 
opt imizat ion of pH -d ep endent,  colon-target ed,  
sustained -r elease mesa la mine microsph eres,  AAPS 
PharmSci Tech,  2011, 13(1), 75-84. 
5. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Hollow 
microspheres for use as a floating controlled drug delivery system 
in the stomach, J Pharm Sci, 1992, 81, 135–140. 
6. Utreja S., Jain NK, Solid lipid nanoparticles. In: Advances in 
controlled and novel drug delivery. 1
st
 ed. New Delhi: CBS 
Publishers and Distributors; 2001.P. 408-424. 
7. Chi SC, Jun HW, Anti-inflammatory activity of ketoprofen gel on 
carrageenan-induced paw edema in rats, Journal of Pharmaceutical 
Sciences, 1990, 79, (11), 974–977. 
8. Lee PI, Kinetics of drug release from hydrogel matrices, J 
Controlled Rel, 1985, 2, 277- 288. 
 
